Intrexon Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
23,760.00
71,930.00
173,605.00
190,926.00
230,981.00
160,574
Cost of Goods Sold (COGS) incl. D&A
-
29,675.00
63,929.00
61,639.00
62,788.00
63,287
Gross Income
-
42,255.00
109,676.00
129,287.00
168,193.00
97,287
SG&A Expense
74,578.00
111,194.00
254,217.00
250,221.00
286,722.00
305,693
EBIT
58,023.00
68,939.00
144,541.00
120,934.00
118,529.00
208,406
Unusual Expense
17,858.00
11,492.00
64,553.00
63,126.00
19,361.00
297,204
Non Operating Income/Expense
162.00
168.00
1,314.00
1,700.00
3,599.00
29,570
Interest Expense
141.00
666.00
1,244.00
861.00
611.00
8,530
Pretax Income
40,908.00
85,719.00
86,978.00
194,151.00
129,700.00
536,234
Income Tax
-
103.00
1,016.00
3,877.00
2,880.00
21,528
Consolidated Net Income
59,299.00
85,616.00
87,994.00
190,274.00
126,820.00
514,706
Net Income
57,371.00
81,822.00
84,493.00
186,612.00
117,018.00
509,336
Net Income After Extraordinaries
57,371.00
81,822.00
84,493.00
186,612.00
117,018.00
509,336
Net Income Available to Common
57,371.00
81,822.00
84,493.00
186,612.00
117,018.00
509,336
EPS (Basic)
1.40
0.83
0.76
1.58
0.98
3.93
Basic Shares Outstanding
40,952.00
99,170.70
111,066.40
117,983.80
119,998.80
129,521.70
EPS (Diluted)
1.40
0.83
0.76
1.58
0.98
3.93
Diluted Shares Outstanding
40,952.00
99,170.70
111,066.40
117,983.80
119,998.80
129,521.70
EBITDA
50,818.00
58,524.00
126,798.00
96,362.00
87,384.00
175,294
Non-Operating Interest Income
166.00
806.00
1,884.00
10,190.00
19,485.00
19,084
Minority Interest Expense
1,928.00
3,794.00
3,501.00
3,662.00
9,802.00
5,370
Equity in Affiliates (Pretax)
606.00
5,260.00
8,944.00
21,120.00
14,283.00
11,608
Other After Tax Income (Expense)
18,391.00
-
-
-
-
-

About Intrexon

View Profile
Address
20374 Seneca Meadows Parkway
Germantown Maryland 20876
United States
Employees -
Website http://www.dna.com
Updated 07/08/2019
Intrexon Corp. is a biotechnology company, which engages in the business of synthetic biology. It focuses on on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The firm offers UltraVector, RheoSwitch, cell systems informatics, protein engineering, and antibody discovery.